Caspian Journal of Internal Medicine
Babol University of Medical Sciences
Wed, Sep 23, 2026
[Archive]
Volume 17, Issue 4 (Autumn 2026)
Caspian J Intern Med 2026, 17(4): 0-2 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Wang L, Chen G, Gong P, Ma J, Yu F, Guan B. Expression and clinical significance of TRIM41 in colon cancer. Caspian J Intern Med 2026; 17 (4)
URL: http://caspjim.com/article-1-4875-en.html
URL: http://caspjim.com/article-1-4875-en.html
Jinhu County People's Hospital , 15189521184@163.com
Abstract: (75 Views)
Background:Exploring the expression of TRIM41 in colon cancer and its clinical significance.
Methods:Immunohistochemistry EVision method was used to detect the expression of TRIM41 protein in 115 colon cancers and normal tissues adjacent to the cancers, and to analyze its relationship with clinicopathological characteristics of colon cancer; GSEA software was applied to To analyze the related signaling pathway of TRIM41 and immune cell infiltration analysis.
Results:TCGA database showed that TRIM41 was highly expressed in colon cancer (P < 0.001). Survival analysis showed that the overall survival of colon cancer patients with low expression of TRIM41 was significantly higher than that of patients with high expression, and high expression of TRIM41 was associated with poor prognosis of colon cancer patients.X2 test showed that the expression level of TRIM41 was correlated with the degree of tumor differentiation (P=0.002) and the grade of tumor outgrowth (P=0.009) in colon cancer patients.GESA analysis showed that TRIM41 high expression was significantly enriched in signaling pathways such as DNA replication, Fanconi anemia pathway and steroid synthesis. Immunocyte infiltration analysis revealed that the level of CD8+ T-cell infiltration was significantly higher in patients with high TRIM41 expression than in patients with low TRIM41 expression (P=0.01001), and the level of granulocyte infiltration in patients with low expression, was significantly higher than in patients with high expression (P=0.00081).
Conclusion: TRIM41 protein expression is associated with the occurrence and development of colon cancer, and high TRIM41 expression is one of the factors associated with poor prognosis of colon cancer patients.
Methods:Immunohistochemistry EVision method was used to detect the expression of TRIM41 protein in 115 colon cancers and normal tissues adjacent to the cancers, and to analyze its relationship with clinicopathological characteristics of colon cancer; GSEA software was applied to To analyze the related signaling pathway of TRIM41 and immune cell infiltration analysis.
Results:TCGA database showed that TRIM41 was highly expressed in colon cancer (P < 0.001). Survival analysis showed that the overall survival of colon cancer patients with low expression of TRIM41 was significantly higher than that of patients with high expression, and high expression of TRIM41 was associated with poor prognosis of colon cancer patients.X2 test showed that the expression level of TRIM41 was correlated with the degree of tumor differentiation (P=0.002) and the grade of tumor outgrowth (P=0.009) in colon cancer patients.GESA analysis showed that TRIM41 high expression was significantly enriched in signaling pathways such as DNA replication, Fanconi anemia pathway and steroid synthesis. Immunocyte infiltration analysis revealed that the level of CD8+ T-cell infiltration was significantly higher in patients with high TRIM41 expression than in patients with low TRIM41 expression (P=0.01001), and the level of granulocyte infiltration in patients with low expression, was significantly higher than in patients with high expression (P=0.00081).
Conclusion: TRIM41 protein expression is associated with the occurrence and development of colon cancer, and high TRIM41 expression is one of the factors associated with poor prognosis of colon cancer patients.
Policy Brief: Review Article |
Subject:
Gastroentrology
Received: 2025/08/12 | Accepted: 2026/08/18 | Published: 2026/09/9
Received: 2025/08/12 | Accepted: 2026/08/18 | Published: 2026/09/9
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
